Saturday 17 October 2026 Export QGEN’s income statement to Excel — free account

QIAGEN N.V.

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%

Follow QGEN

Alert me

Market cap: $9.5B
P/E: 23.6×
Fwd P/E: 17.5×
Dividend yield: 0.76%
F-score: 8/9
Altman Z: 3.81
Beneish M: −2.60
Dividend safety: 66/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.73%

Capital & Financial Ratios $m

Market Cap 9,510.00

Revenue 2,100.36

Net Income 409.32

Free Cash Flow 440.60

Net Debt 850.12

Current Ratio 2.85

Debt/Equity 0.49

P/E ratio 23.64

Fwd P/E 17.50

P/S ratio 4.53

P/B ratio 2.83

Past 5Y EPS Growth 2.58%

This Y EPS Growth 2.30%

Next Y EPS Growth 7.63%

Next Y revenue growth 2.15%

Next 5Y EPS Growth 6.38%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 24.48%

10-year low 10-year high

P/S against its own 10 years 25.03%

10-year low 10-year high

P/B against its own 10 years 52.82%

10-year low 10-year high

EV/Sales against its own 10 years 31.07%

10-year low 10-year high

EV/FCF against its own 10 years 26.43%

10-year low 10-year high

Dividends

Payout Ratio 0.18

Annual Dividend Rate 0.35

Annual Dividend Yield 0.76%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.14	0.35
2025	0.20	1.36 0.26
2024	1.37	1.37
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,058	1,153	1,099	794
Receivables	382	349	403	390
Inventory	398	279	302	311
Other	—	—	—	—
	2,148	1,960	1,995	1,657

	2023	2024	2025	Q'26
Payables	84	83	73	79
ST’ Debt	588	552	—	17
Other	—	—	—	—
	1,079	1,042	512	581

Compound Annual Growth %

	10y	5y	3y
Sales	5.02%	2.25%	(0.81%)
Cash Flow	7.50%	7.40%	(2.92%)
Earnings	12.56%	3.42%	0.13%
Book Value	3.94%	6.19%	2.91%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	492	535	—	—	—
’25	483	534	533	540	2,090
’24	459	496	502	521	1,978
’23	485	495	476	509	1,965
’22	628	516	500	498	2,142
’21	567	567	535	582	2,252
’20	372	443	484	571	1,870

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	101	201	—	—	—
’25	140	161	165	188	654
’24	133	167	182	192	674
’23	72	111	125	151	459
’22	207	172	212	124	715
’21	129	156	156	198	639
’20	16	135	37	270	458

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	52	157	—	—	—
’25	95	121	115	117	447
’24	95	128	138	142	502
’23	34	80	84	99	297
’22	169	134	185	78	566
’21	74	110	104	144	432
’20	(12)	13	(50)	203	154

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.33	0.50	—	—	—
’25	0.43	0.46	0.63	0.49	1.94
’24	0.39	(0.90)	0.48	0.41	0.39
’23	0.41	0.39	0.38	0.45	1.60
’22	0.75	0.47	0.40	0.44	2.05
’21	0.63	0.58	0.64	0.63	2.47
’20	0.19	0.42	0.08	1.02	1.71

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	21.39	28.39	31.76	25.84	34.02	47.04	41.67	35.85	39.03	37.63	Analyst estimates 2026–2028 Powerpack
	High	30.94	37.50	40.71	44.54	57.04	60.89	56.88	52.82	47.44	51.88
People
People	Employees	4,684	4,688	4,952	5,096	5,610	6,000	6,178	5,967	5,765	5,654
	Revenue/emp, $m	0.29	0.30	0.30	0.30	0.33	0.38	0.35	0.33	0.34	0.37
Income, $m
Income, $m	Revenue	1,338	1,418	1,502	1,526	1,870	2,252	2,142	1,965	1,978	2,090
	Gross margin, %	63.13	65.08	66.65	65.86	65.91	64.43	64.65	62.77	48.90	62.18
	EBT	57	114	226	(78)	439	626	513	430	121	490
	EBT margin, %	4.25	8.07	15.03	(5.10)	23.50	27.79	23.94	21.87	6.12	23.46
	Net income	80	40	190	(41)	359	513	423	341	84	425
	Depreciation	234	241	242	272	247	247	242	235	222	197
Per share, $
Per share, $	Revenue	6.36	6.94	7.40	7.51	9.14	11.02	10.19	9.07	8.89	9.62
	Earnings	0.38	0.19	0.92	(0.20)	1.71	2.47	2.05	1.60	0.39	1.94
	Cash flow	1.62	1.40	1.77	1.63	2.24	3.13	3.40	2.12	3.03	3.01
	Capex	(0.45)	(0.61)	(0.74)	(1.35)	(1.49)	(1.01)	(0.71)	(0.75)	(0.77)	(0.95)
	Free cash flow	1.18	0.79	1.03	0.28	0.75	2.12	2.69	1.37	2.26	2.06
	Book value	12.39	12.44	12.98	12.49	13.67	15.16	16.49	17.57	16.02	17.39
	Shares, m	210	204	203	203	205	204	210	217	223	217
Valuation, ×
Valuation, ×	P/E	79.51	170.50	38.84	0.00	31.93	23.25	25.09	27.50	117.80	22.30
	P/S	4.76	4.66	4.81	4.64	5.97	5.20	5.06	4.97	5.01	4.67
	P/B	2.44	2.60	2.74	2.79	3.99	3.78	3.12	2.56	2.78	2.59
	EV/Sales	5.16	5.18	5.26	5.19	6.61	5.59	5.26	5.20	5.13	5.18
	EV/FCF	27.86	45.23	37.83	141.64	80.54	29.12	19.92	34.44	20.21	24.20
Cash, $m
Cash, $m	Operating cash flow	342	287	359	331	458	639	715	459	674	654
	Capex	(94)	(124)	(151)	(275)	(304)	(207)	(149)	(163)	(171)	(207)
	Free cash flow	248	162	209	56	154	432	566	297	502	447
Balance, $m
Balance, $m	Working capital	729	1,323	1,183	619	1,052	592	1,419	1,068	918	1,483
	Total debt	1,072	1,768	2,174	1,706	1,923	1,942	1,861	1,510	1,392	1,654
	Net debt	540	744	678	840	1,208	876	443	452	239	556
	Shareholders’ equity	2,607	2,541	2,635	2,537	2,798	3,097	3,467	3,808	3,567	3,778
Returns, %
Returns, %	ROA	1.89	0.86	3.53	(0.75)	6.47	8.53	6.81	5.50	1.42	7.10
	ROIC	1.96	2.92	5.03	(0.48)	6.03	9.91	8.50	6.01	1.60	6.72
	ROE	3.11	1.57	7.36	(1.60)	13.47	17.39	12.90	9.38	2.27	11.57

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MEDP Medpace Holdings, Inc.	$17.6B	35.6×	26.7×	+17.24% (above 0%: growing)	+36.39% (above 0%: growing)	−3.03% (below 0%: shrinking)	71.36%	20.76%	Compare
RVTY Revvity Inc.	$17.3B	72.7×	37.5×	+1.31% (above 0%: growing)	+2.17% (above 0%: growing)	+59.29% (above 0%: growing)	57.13%	12.24%	Compare
CRL Charles River Laboratories International, Inc.	$14.6B	— (loss-making)	29.6×	−2.72% (below 0%: shrinking)	n/m	−12.22% (below 0%: shrinking)	36.19%	11.94%	Compare
ICLR ICON PLC	$13.5B	254×	23.8×	+1.20% (above 0%: growing)	−59.31% (below 0%: shrinking)	+109.66% (above 0%: growing)	23.23%	6.68%	Compare
QGEN QIAGEN N.V.	$9.5B	23.6×	17.5×	+0.28% (above 0%: growing)	+7.94% (above 0%: growing)	+30.45% (above 0%: growing)	63.62%	24.75%
TWST Twist Bioscience Corporation	$9.5B	— (loss-making)	— (loss-making)	+23.24% (above 0%: growing)	n/m	−7.23% (below 0%: shrinking)	52.76%	(30.65%)	Compare
GRAL GRAIL, Inc.	$6.1B	— (loss-making)	— (loss-making)	+25.72% (above 0%: growing)	n/m	−4.95% (below 0%: shrinking)	(28.12%)	(388.89%)	Compare
RDNT RadNet, Inc.	$5.5B	— (loss-making)	279×	+24.99% (above 0%: growing)	−47.37% (below 0%: shrinking)	−43.22% (below 0%: shrinking)	14.14%	6.34%	Compare
SHC Sotera Health Company	$5.2B	31.4×	23.7×	+9.18% (above 0%: growing)	+533.33% (above 0%: growing)	+60.56% (above 0%: growing)	55.38%	33.23%	Compare
Median of peers	$11.5B	54.1×	28.2×	+13.21%	+2.17%	−3.99%	44.48%	9.31%

All 52 Diagnostics & Research stocks →

QIAGEN N.V. (QGEN) key facts

Strength: QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
QIAGEN N.V. (QGEN) is a Diagnostics & Research company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, QGEN traded at $46.13, a market capitalization of $9.5 billion.
QIAGEN N.V. pays an annual dividend of $0.35 per share, a yield of 0.76%, with a payout ratio of 17.9%.
Return on equity was 11.6% and debt-to-equity 0.49.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 3.81 (safe zone) for fiscal 2025.